Senores Pharma: No IPO Fund Use Deviation in Q3 FY27
Senores Pharmaceuticals Limited has submitted its statement of deviation or variation in the utilization of public issue funds for the quarter ended September 30, 2026. The company confirmed no deviation from the original or modified objects stated in its prospectus. The utilization of the ₹500 Crore IPO proceeds was reviewed by the Audit Committee and approved by the Board of Directors. While most fund allocations remained as planned, minor adjustments were made, such as ₹6.98 Crore utilized for investment in subsidiary Havix for capital expenditure, revised from an original allocation of ₹107.00 Crore. Other minor variations included ₹0.38 Crore for repayment of borrowings and ₹0.02 Crore for re-payment of borrowings for subsidiaries. New objectives for investment in subsidiaries SPI and Apnar were added as per shareholder approval.
Key Highlights
- No deviation reported in IPO fund utilization for Q3 FY27.
- ₹500 Crore IPO proceeds were managed without significant variance.
- Minor fund reallocations occurred for subsidiary investments and debt repayment.
- Audit Committee and Board of Directors reviewed and approved the fund utilization statement.
- New investment objectives for subsidiaries were added post shareholder approval.
Price Impact
More from SENORES